Shuttle Pharmaceuticals Holdings

Company snapshot

Shuttle Pharmaceuticals is a clinical-stage pharmaceutical company developing novel therapies and diagnostics to improve the outcomes for cancer patients treated with radiation therapy. Our technology sensitizes growing cancer cells, rendering them susceptible to the effects of radiation therapy, activates DNA damage and innate immune responses and offers the potential to integrate with checkpoint

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 9 US patent(s) indexed to this assignee profile.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Shuttle Pharmaceuticals Holdings. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Shuttle Pharmaceuticals Holdings.

1. May 23, 2026 Clinical update

   Ropidoxuridine — Phase 2

2. Jul 15, 2025 Patent grant

   Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorlylase inhibitors in combination with radiation

3. Sep 3, 2024 Patent grant

   Selective histone deacetylase inhibitors for the treatment of human disease

4. May 23, 2023 Patent grant

   Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation

5. Feb 21, 2023 Patent grant

   Selective histone deacetylase inhibitors for the treatment of human disease

View all clinical trial activity →

• What is Shuttle Pharmaceuticals Holdings?

  Shuttle Pharmaceuticals is a pharma organization headquartered in Rockville, USA. It trades on NYSE under ticker SHPH. Primary therapeutic focus areas include Glioblastoma, IDH-wildtype. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 9 patent record(s) to this

• Is Shuttle Pharmaceuticals Holdings publicly traded?

  Yes. Shuttle Pharmaceuticals Holdings is listed with ticker SHPH on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Shuttle Pharmaceuticals Holdings develop or market?

  We link 1 drug profile(s) where Shuttle Pharmaceuticals Holdings is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/shuttle-pharmaceuticals-holdings#company-drugs.

• What are the latest developments for Shuttle Pharmaceuticals Holdings?

  In the last 12 months our linked public records show 1 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Shuttle Pharmaceuticals Holdings focus on?

  Shuttle Pharmaceuticals Holdings focuses on Glioblastoma, IDH-wildtype based on our analysis of their pipeline programs and drug development activities.